Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
70.9M
-
Number of holders
-
114
-
Total 13F shares, excl. options
-
60.9M
-
Shares change
-
+2.84M
-
Total reported value, excl. options
-
$281M
-
Value change
-
+$7.12M
-
Put/Call ratio
-
0.44
-
Number of buys
-
65
-
Number of sells
-
-55
-
Price
-
$4.62
Significant Holders of C4 Therapeutics, Inc. - Common Stock (CCCC) as of Q2 2024
143 filings reported holding CCCC - C4 Therapeutics, Inc. - Common Stock as of Q2 2024.
C4 Therapeutics, Inc. - Common Stock (CCCC) has 114 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 60.9M shares
of 70.9M outstanding shares and own 85.88% of the company stock.
Largest 10 shareholders include Lynx1 Capital Management LP (6.88M shares), RA CAPITAL MANAGEMENT, L.P. (4.88M shares), WASATCH ADVISORS LP (4.85M shares), BlackRock Inc. (4.55M shares), Soleus Capital Management, L.P. (4.05M shares), VANGUARD GROUP INC (3.56M shares), COMMODORE CAPITAL LP (3.41M shares), STATE STREET CORP (2.99M shares), Balyasny Asset Management L.P. (1.94M shares), and BANK OF AMERICA CORP /DE/ (1.77M shares).
This table shows the top 114 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.